What is a Patient Information Leaflet and why is it useful?

The Patient Information Leaflet (PIL) is the leaflet included in the pack with a medicine. It is written for patients and gives information about taking or using a medicine. It is possible that the leaflet in your medicine pack may differ from this version because it may have been updated since your medicine was packaged.

Black triangle. This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information.

Below is a text only representation of the Patient Information Leaflet. The original can be viewed in PDF format using the link above.

The text only version may be available from RNIB in large print, Braille or audio CD. For further information call RNIB Medicine Leaflet Line on 0800 198 5000. The product code(s) for this leaflet is: EU/1/15/1084/001.

Portrazza 800 mg concentrate for solution for infusion

Package leaflet: Information for the user

Portrazza® 800 mg concentrate for solution for infusion

necitumumab

▼ This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects.

Read all of this leaflet carefully before you are given this medicine because it contains important information for you.

  • Keep this leaflet. You may need to read it again.
  • If you have any further questions, ask your doctor.
  • If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet

1. What Portrazza is and what it is used for
2. What you need to know before you are given Portrazza
3. How you are given Portrazza
4. Possible side effects
5. How to store Portrazza
6. Contents of the pack and other information

1. What Portrazza is and what it is used for

Portrazza contains the active substance necitumumab, which belongs to a group of substances called monoclonal antibodies.

Necitumumab recognises and binds specifically to a protein on the surface of some cancer cells. The protein is known as epidermal growth factor receptor (EGFR). Other body proteins (called growth factors) can attach to the EGFR and stimulate the cancer cell to grow and divide. Necitumumab hinders other proteins from binding to the EGFR and thus prevents the cancer cell from growth and division.

Portrazza is used in combination with other anti-cancer medicines for the treatment of adults with certain type of lung cancer at an advanced stage (squamous non-small cell lung cancer), whose cancer cells have the EGFR protein on their surface. The anti-cancer medicines it is combined with are gemcitabine and cisplatin.

2. What you need to know before you are given Portrazza

You must not be given Portrazza

  • if you have ever had a severe allergic reaction to necitumumab or any of the other ingredients of this medicine (listed in section 6).

Warnings and precautions

Talk to your doctor or nurse immediately if any of the following applies to you (or you are not sure) during or after treatment with Portrazza:

  • Blood clots in the arteries or the veins
    Portrazza can cause blood clots in your arteries or your veins. Symptoms may include swelling, pain and tenderness of the limb, difficulty breathing, chest pain, or an abnormal heartbeat and discomfort. Your doctor will discuss with you whether you need any preventive measures. See also section 4 for the symptoms of blood clots.
  • Cardiorespiratory disorders
    Cases of cardiorespiratory disorders and unexplained death were observed in patients treated with Portrazza in combination with gemcitabine and cisplatin and in patients treated with gemcitabine and cisplatin alone. The causes of these deaths and their relationship to treatment were not always known. Portrazza may increase this risk. Your doctor will discuss this with you.
  • Infusion-related reaction
    Infusion-related reactions may occur during treatment with Portrazza. Such reactions may be allergic. Your doctor will discuss with you whether you need any preventive measures or early treatment. Your doctor or nurse will check for side effects during your infusion. If you have a severe infusion-related reaction, your doctor may recommend adjusting the dose of Portrazza, or stop your treatment with Portrazza. See section 4 for more details about infusion-related reactions which may occur during or after the infusion.
  • Skin reactions
    Portrazza may cause side effects involving the skin. Your doctor will discuss with you whether you need any preventive measures or early treatment. If you have a severe skin reaction, your doctor may recommend adjusting the dose of Portrazza, or stop your treatment with Portrazza. See section 4 for more details about skin reactions.
  • Blood levels of magnesium, calcium, potassium and phosphate
    During treatment, your doctor will check your blood periodically for levels of several substances such as magnesium, calcium, potassium and phosphate. If these levels are too low, your doctor may prescribe appropriate supplements.
  • Infections
    If you have signs of infection before start of treatment please tell your doctor.

Children and adolescents

Portrazza should not be given to patients under the age of 18 years because there is no information about how it works in this age group.

Other medicines and Portrazza

Tell your doctor if you are taking, have recently taken or might take any other medicines. This includes medicines obtained without a prescription and herbal medicines.

Pregnancy and breast-feeding

Before starting treatment you must tell your doctor if you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby.

Avoid getting pregnant while receiving this medicine and for at least 3 months after the last dose of Portrazza as this medicine may potentially cause harm to your unborn child. Talk to your doctor about the best contraception for you.

Do not breast-feed your baby during treatment with Portrazza and for at least 4 months after you receive the last dose, as this medicine may harm the growth and development of your baby.

Driving and using machines

If you experience any symptoms affecting your ability to concentrate and react, do not drive or use machines until the effect goes away.

Portrazza contains sodium

This medicine contains 76 mg sodium per dose. This should be taken into consideration by patients on a controlled sodium diet.

3. How you are given Portrazza

A doctor experienced in the use of anti-cancer medicines will supervise your Portrazza therapy.

Premedication

You may be given medicines to reduce the risk of an infusion-related reaction or a skin reaction before you receive Portrazza.

Dose and administration

The recommended dose of Portrazza is 800 mg on days 1 and 8 of each 3-week cycle. Portrazza is given in combination with the medicines gemcitabine and cisplatin for up to 6 cycles and then it is given on its own. The number of infusions that you receive will depend on how and for how long you respond to treatment with Portrazza. Your doctor will discuss this with you.

This medicine is given as an intravenous (into a vein) infusion via a drip. The drip lasts about 60 minutes.

Detailed instructions for your doctor or your nurse on how to prepare Portrazza infusion are included at the end of this package leaflet (see ‘Handling instructions’).

Dose adjustments

During each infusion, your doctor or nurse will check for side effects. If you have an infusion-related reaction during treatment, your drip will be slowed down and future doses will also be given more slowly. The infusion duration should not exceed 2 hours. See also section 2 under “Warnings and precautions”.

4. Possible side effects

Like all medicines, this medicine can cause side effects, although not everybody gets them.

The important side effects of Portrazza are skin reactions and blood clots in the veins.

Seek medical help immediately if you experience any of the following:

Blood clots in the veins

Venous blood clots are likely to occur in approximately 8 out of 100 patients. In approximately 4 out of 100 patients these side effects are likely to be severe. They can lead to a blockage of a blood vessel in the leg. Symptoms may include swelling, pain and tenderness of the limb. Blood clots can also lead to a blockage in the blood vessels of the lung. Symptoms may include difficulty breathing, chest pain, or an abnormal heartbeat and discomfort.

Skin reactions

Skin reactions may occur in approximately 80 out of 100 patients who take Portrazza and are usually mild to moderate. In approximately 5 out of 100 patients these skin reactions are likely to be severe. Symptoms of severe skin reactions may include acne-like skin conditions and skin rash. The skin rash commonly resembles acne and often involves the face, upper chest and back, but can affect any area of the body. Most of these side effects usually disappear over time after the end of Portrazza therapy.

Other side effects include:

Very common (may affect more than 1 in 10 people):

  • itching; dry skin; scaling; nail disorders (skin reactions)
  • vomiting
  • fever or high temperature (pyrexia)
  • decreased weight
  • mouth ulcers and cold sores (stomatitis)

Common (may affect up to 1 in 10 people)

  • headache
  • coughing up blood (haemoptysis)
  • nosebleed (epistaxis)
  • strange tastes; metallic taste (dysgeusia)
  • eye inflammation (conjunctivitis)
  • blood clots in the arteries
  • urinary tract infection (bladder and/or kidneys)
  • pain when passing urine (dysuria)
  • difficulty in swallowing (dysphagia)
  • muscle spasms
  • inflammation of veins in the legs (phlebitis)
  • allergic reactions
  • pain in your mouth and throat (oropharyngeal pain)

Portrazza may also cause changes in the results of blood tests. These include low blood levels of magnesium, calcium, potassium or phosphate.

Reporting of side effects

If you get any side effects, talk to your doctor. This includes any possible side effects not listed in this leaflet. You can also report side effects directly via

Ireland:

HPRA Pharmacovigilance
Earlsfort Terrace
IRL - Dublin 2
Tel: +353 1 6764971
Fax: +353 1 6762517
website: www.hpra.ie

Malta:

ADR Reporting
website: www.medicinesauthority.gov.mt/adrportal

or the

United Kingdom:

Yellow Card Scheme
website: www.mhra.gov.uk/yellowcard

By reporting side effects you can help provide more information on the safety of this medicine.

5. How to store Portrazza

Keep this medicine out of the sight and reach of children.

Do not use this medicine after the expiry date which is stated on the outer carton and vial label after EXP. The expiry date refers to the last day of that month.

Store in a refrigerator (2 °C - 8 °C).

Do not freeze.

Keep the vial in the outer carton in order to protect from light.

Infusion solution: After dilution and preparation, the medicine must be used immediately. If not used immediately, in-use storage times and conditions prior to use are the responsibility of the user and would normally not be longer than 24 hours at 2 to 8 °C, or up to 4 hours at 9 °C to 25 °C. Do not freeze or shake the infusion solution. Do not administer the solution if you notice any particulate matter or discoloration.

This medicine is for single use only.

Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.

6. Contents of the pack and other information

What Portrazza contains

  • The active substance is necitumumab. Each millilitre of the concentrate for solution for infusion contains 16 mg of necitumumab.
    Each 50 mL vial contains 800 mg of necitumumab.
  • The other ingredients are sodium citrate dihydrate (E331), citric acid anhydrous (E330), sodium chloride (see section 2Portrazza contains sodium”), glycine (E640), mannitol (E421), polysorbate 80 (E433) and water for injections.

What Portrazza looks like and contents of the pack

Portrazza 800 mg concentrate for solution for infusion (sterile concentrate) is a clear to slightly opalescent and colourless to slightly yellow liquid in a glass vial with a rubber stopper.

It is available in packs of:

  • 1 vial of 50 mL

Marketing Authorisation Holder

Eli Lilly Nederland B.V.
Papendorpseweg 83
3528 BJ Utrecht
The Netherlands

Manufacturer

Lilly S.A.
Avda de la Industria
30, Alcobendas
Madrid
28108
Spain

For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:

United Kingdom
Eli Lilly and Company Limited
Tel: + 44-(0) 1256 315000

This leaflet was last revised in November 2016.

Detailed information on this medicine is available on the European Medicines Agency web site: http://www.ema.europa.eu.